GSK is paying 400 million euros ($430 million) upfront for full rights to CureVac’s vaccines against influenza and COVID-19. GSK is paying the upfront and now committing up to 1.05 billion euros ($1.13 billion) in milestones to take full control of mRNA candidate vaccines for influenza and COVID-19. Source: Fierce Biotech 3/7/2024